Zydus hypertension drug gets US regulatory nod

Image
IANS Ahmedabad
Last Updated : Sep 23 2017 | 10:32 PM IST

Global healthcare provider Zydus Cadila on Saturday said it received approval from the US Federal Drug Authority (USFDA) to market Amlodipine and Olmesartan Medoxomil tablets for the treatment of hypertension.

"The drug, meant for treating hypertension or to lower blood pressure with other anti-hypertensive agents, will be manufactured at our group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad," said the company in a regulatory filing to the BSE.

The company also received the federal regulatory approval on September 21 to market its Itraconazole capsules to treat fungal infections.

--IANS

fb/vd

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 23 2017 | 10:22 PM IST

Next Story